I have a few questions for the panellists today. I first wanted to ask what you think of the life cycle approach, in terms of regulating the health products. It was suggested in the blueprint for renewal in 2006 that this might be a way to have better surveillance. Also, do you expect that progressive licences will be subject to phase four clinical trials? And do you have any idea, on a broader level, of what types of costs would be involved with that?
On February 7th, 2008. See this statement in context.